本次审计依据 EU GMP Guidelines EudraLex Volume 4、EU Clinical Trial Regulation、GMP for IMP 及 ICH Q7 等指导原则，审计范围涵盖了小分子及新分 子 API 业务的质量管理、生产管理、厂房设备设施、物料系统、包装与标签系统 等方面。本次顺利通过 QP 审计，标志着博腾智拓质量管理体系已达到欧盟 GMP 标准，能够为全球客户提供符合国际标准的小分子、多肽与寡核苷酸、蛋白与偶 联药物的定制研发生产服务。 本次通过欧盟 QP 审计不会对公司当前业绩产生较大影响，敬请广大投资者 谨慎决策，注意防范投资风险。 重庆博腾制药科技股份有限公司 关于全资子公司通过欧盟 QP 审计的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）全资子公司上海博腾 智拓医药科技有限公司（以下简称"博腾智拓"）于近日获得欧盟质量受权人 （Qualified Person, QP）签发的符合性声明，顺利通过欧盟 QP 审计。 股票代码：300363 股票简称：博腾股份 ...

Market Overview - The Shanghai Composite Index closed at 3399.77 points, above the six-month moving average, with a gain of 0.43% [1] - The total trading volume of A-shares reached 13126.55 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 220 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 8.76% deviation, closing price at 14.00 yuan, with a daily gain of 16.86% and turnover rate of 21.88% [1] - Haochen Medical: 8.62% deviation, closing price at 3.12 yuan, with a daily gain of 9.86% and turnover rate of 7.25% [1] - Guangyun Technology: 8.13% deviation, closing price at 14.22 yuan, with a daily gain of 9.89% and turnover rate of 6.59% [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - CITIC Special Steel: minor deviation, closing price at 20.30 yuan, with a daily gain of 10.69% [1] - Nanda Optoelectronics: minor deviation, closing price at 36.44 yuan, with a daily gain of 9.99% [1] -沃尔核材: minor deviation, closing price at 25.41 yuan, with a daily gain of 11.75% [1]

Market Overview - The Shanghai Composite Index closed at 3393.26 points, above the six-month moving average, with a change of 0.23% [1] - The total trading volume of A-shares reached 838.618 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 184 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Qitian Technology: 11.69% deviation, closing price 14.38 yuan, with a daily increase of 20.03% and turnover rate of 15.50% [1] - Haochen Medical: 8.62% deviation, closing price 3.12 yuan, with a daily increase of 9.86% and turnover rate of 6.44% [1] - Jinyinhai: 7.58% deviation, closing price 21.00 yuan, with a daily increase of 9.66% and turnover rate of 6.43% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Guangyun Technology: 7.45% deviation, closing price 14.13 yuan, with a daily increase of 9.20% and turnover rate of 4.78% [1] - Yaowang Technology: 5.93% deviation, closing price 7.12 yuan, with a daily increase of 7.88% and turnover rate of 13.64% [1] - Nuotai Biotech: 5.91% deviation, closing price 55.37 yuan, with a daily increase of 10.36% and turnover rate of 5.58% [1] Summary of Other Stocks - Additional stocks with lower deviation rates that have just crossed the six-month moving average include: - Guangdong Hongtu: just above the six-month line [1] - Xinhe Shares: just above the six-month line [1] - Songjing Shares: just above the six-month line [1]

Group 1 - The cell immunotherapy concept index rose by 1.25%, ranking 6th among concept sectors, with 29 stocks increasing in value [1][2] - Notable gainers included Ruizhi Pharmaceutical with a 20% limit up, Hainan Haiyao at limit up, and Shutaishen, Guanhao Biological, and Fosun Pharma with increases of 15.02%, 8.88%, and 5.23% respectively [1][6] - The sector experienced a net outflow of 266 million yuan, with 20 stocks seeing net inflows, and 8 stocks receiving over 10 million yuan in net inflows, led by Hainan Haiyao with a net inflow of 144 million yuan [2][3] Group 2 - Hainan Haiyao, Anke Bio, and Dongcheng Pharmaceutical had the highest net inflow ratios at 35.56%, 5.52%, and 5.27% respectively [3][4] - The top stocks by net inflow included Hainan Haiyao, Fosun Pharma, Ruizhi Pharmaceutical, and Zhaoyan New Drug, with net inflows of 144 million yuan, 54.52 million yuan, 34.78 million yuan, and 31.86 million yuan respectively [2][3] - Stocks with significant declines included Xue Rong Biological, Saifutian, and Jinchang Protein, with decreases of 4.23%, 2.74%, and 2.61% respectively [1][5]

Group 1: Strategic Focus - The company's strategic focus for 2025 is on overseas markets, which account for approximately 75% of its business, and cornerstone business segments that contribute about 90% of revenue [1] - New business segments primarily target domestic customers, with ongoing efforts to develop overseas markets in molecular business and gene cell therapy [1] Group 2: Market Presence and Operations - The company does not have separate operational entities in Japan and South Korea but has business development efforts in these markets, which have shown promising growth since 2024 [2] - The Slovenia R&D and production base serves global clients, with a core customer base primarily from Europe [2] Group 3: Order and Delivery Insights - The average order delivery cycle ranges from 3 to 18 months, depending on project requirements, with no significant seasonal delivery patterns [2] - Specific data on Q1 2025 orders was not disclosed due to reporting constraints [2] Group 4: Financial Performance and Projections - The revenue from the formulation business declined by 40% in Q1 2025, primarily due to project delivery timing [3] - The company's gross margin is in a recovery phase, with the core business segment of small molecule APIs maintaining a gross margin of approximately 33% in 2024 [3] - The company aims to enhance revenue scale and introduce more high-value projects to optimize product structure and improve operational efficiency for sustained gross margin recovery [3]

| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

重庆博腾制药科技股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日召 开第六届董事会第一次临时会议，审议通过《关于续聘公司高级管理人员的议案》 《关于续聘公司证券事务代表的议案》，同意公司续聘高级管理人员及证券事务 代表事项。具体情况如下： 股票代码：300363 股票简称：博腾股份 公告编号：2025-030号 重庆博腾制药科技股份有限公司 关于续聘高级管理人员及证券事务代表的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 同意续聘居年丰先生为公司总经理，白银春先生为公司高级副总经理、首席 运营官，陈晖先生为公司副总经理、首席财务官，皮薇女士为公司副总经理、董 事会秘书，朱坡先生、陈琪先生为公司副总经理，汪星星女士为公司证券事务代 表。 上述人员任期均自公司董事会审议通过之日起至第六届董事会届满时止。上 述人员简历见附件。上述人员的任职资格符合《中华人民共和国公司法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等法律法规，以及公司《公司章程》等相关规定。 董事会秘书皮薇女士、 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-031 号 重庆博腾制药科技股份有限公司 第六届监事会第一次临时会议决议公告 根据《公司章程》《监事会议事规则》的相关规定，为保障公司第六届监事 会各项工作的顺利开展，同意选举谭永庆先生为公司第六届监事会主席，任期自 本次监事会审议通过之日起至公司第六届监事会届满时止。 公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）第六届监事会第一次 临时会议于 2025 年 5 月 8 日（星期四）以通讯会议方式召开，会议通知已于 2025 年 4 月 29 日通过电子邮件方式送达各位监事。本次会议应参与表决监事人数 3 人，实际参与表决监事人数 3 人，经公司全体监事共同推举，本次会议由监事谭 永庆先生主持。 会议在保证所有监事充分发表意见的前提下，以投票的方式进行表决。会议 召开符合《中华人民共和国公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 经与会监事认真审议，以投票表决方式通过以下议案： 1、审议通过《关于选举公司第六届监事会主席的 ...

股票代码：300363 股票简称：博腾股份 公告编号：2025-029 号 重庆博腾制药科技股份有限公司 第六届董事会第一次临时会议决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过《关于选举第六届董事会各专门委员会成员的议案》； 根据《公司章程》《董事会议事规则》等相关规定，公司第六届董事会下设 审计委员会、提名委员会、薪酬与考核委员会、战略与 ESG 委员会等四个专门 委员会，各专门委员会组成建议如下： 审计委员会：庞金伟（主任委员）、袁林、曹国华 重庆博腾制药科技股份有限公司（以下简称"公司"）第六届董事会第一次 临时会议于 2025 年 5 月 8 日（星期四）以通讯会议方式召开，会议通知已于 2025 年 4 月 29 日通过电子邮件方式送达各位董事。本次会议应参与表决董事人数 7 人，实际参与表决董事人数 7 人。经公司全体董事共同推举，本次会议由董事居 年丰先生主持，公司部分监事、高级管理人员列席会议。 会议召开符合《公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 会议在保证所有董事充分发表意见的前提下，以 ...

Group 1: Xiangsheng Medical - The company emphasizes shareholder returns, with a 2024 dividend plan of 10 CNY per 10 shares, totaling 112 million CNY, which accounts for 79.62% of net profit [1] - In 2024, the company plans to invest nearly 80 million CNY in R&D, with 48 new patent authorizations and 5 domestic and 35 international market access licenses [1] - The breast artificial intelligence ultrasound robot is designed for breast cancer screening, integrating ultrasound, robotics, and AI technology for large-scale patient screening [1] - The company is mitigating risks from US tariffs through global market expansion and ODM models, aiming to build a global supply chain and explore emerging markets [1] Group 2: Boteng Co., Ltd. - Despite external uncertainties, the company remains a key supply chain partner for clients, with limited impact from current tariff policies as products fall within the exemption range [2] - The company's gross margin fluctuations are mainly influenced by domestic market conditions and new business losses, while overseas markets and core business margins remain stable [2] - The company has increased production and R&D capabilities through acquisitions and self-construction, with a growing order backlog expected to convert into revenue in 2024 and 2025 [2] - New molecular business is growing rapidly, but the timeline for reaching breakeven is uncertain, with 2025 capital expenditures focused on overseas expansion and upgrading existing capacities [2] Group 3: ST Huatuo - The company focuses on evergreen game categories like SLG and match-3 games, emphasizing innovation and scalability [3] - The company believes that the trend for SLG games is favorable due to ease of operation and strong user retention, although successful teams are limited [3] - The company plans to leverage cost reduction and efficiency improvements to return to traditional advantages and explore overseas markets [3] - The company is optimistic about AI game development, hosting innovation competitions while maintaining a cautious short-term outlook [3]